양안 당뇨황반부종에서 각각 시행한 유리체강내 트리암시놀론과 베바시주맙 주입의 단기효과 비교 |
김남억, 이수정, 박정민 |
1Department of Ophthalmology, Maryknoll Medical Center, 2Department of Ophthalmology, Inje University Haeundae Paik Hospital, Busan, Korea |
Short Term Effect of Intravitreal Triamcinolone Acetonide versus Bevacizumab in Bilateral Diabetic Macular Edema |
Nam Eok Kim, Soo Jung Lee, Jung Min Park |
|
Abstract |
Purpose To compare the effect of a single intravitreal injection of triamcinolone acetonide and bevacizumab for the treatment of diabetic macular edema. Methods: Forty eyes of 20 patients with bilateral diabetic macular edema participated in this study. In each patient, one eye was treated with a single intravitreal injection of bevacizumab 1.25 mg/0.05 ml (IVBI group) and the other eye with a single intravitreal injection of 4 mg/0.1 ml triamcinolone (IVTI group). Comprehensive Ophthalmic examination was peformed at baseline and at 1, 3 months after treatment. Main outcome measures included best corrected visual acuity (logMAR) and intraocular pressure and central macular thickness measured with optical coherence tomography (OCT). Results: Central macular thickness (CMT) was reduced significantly in both IVTI an IVBI group at 1 month (p=0.002, 0.012). But CMT was reduced significantly only in IVTI group at 3 months (p=0.003). Mean best corrected visual acuity was not improved significantly in both groups at 1, 3 months. Intraocular pressure elevation was significantly in IVTI group at 1, 3 months (p=0.004, 0.003). And there was a significant difference between both group about IOP (p=0.014, 0.041). Conclusions: One single intravitreal injection of triamcinolone offer better advantage over bevacizumab in the short term management of diabetic macular edema, with regard to changes in central macular edema. But there was no significant improvement of best corrected visual acuity in both group, also not a significant difference between both group. Special attention was needed in triamcinolone group about elevation of intraocular pressure. (Korean J Optom Vis Sci 2012;11(1):84-90) |
Key Words:
Bevacizumab, Diabetic macular edema, Triamcinolone acetonide |
|